Misti Ushio is a Board Director at Digitalis Commons, and a Managing Partner at Digitalis Ventures.
Dr. Ushio is formerly the CEO of TARA Biosystems which was acquired by ValoHealth in 2022. TARA Biosystems developed physiologically relevant 3D tissue models for drug discovery and development applications and accelerated discovery efforts for novel heart medicines via its disease modeling and phenotypic screening capabilities.
Dr. Ushio has over 25 years of experience in the biotechnology and pharmaceutical industry, and early-stage life science company building. Dr. Ushio has served most recently as Chief Strategy Officer and Managing Director of Harris & Harris Group, where she advised and invested in life science companies to help them translate their transformational science into commercially successful companies.
Earlier in her career, Dr. Ushio held management roles at Merck & Company, where she developed vaccines and biologics products, and Columbia University, where she managed the intellectual property of several scientific and engineering portfolios.
She was graduated from Johns Hopkins University (B.S., Chemical Engineering), Lehigh University (M.S., Chemical Engineering) and University College London (Ph.D., Biochemical Engineering). She also has served as a Director on the boards of private and public life science companies. In 2018, she was named to Fast Company’s Top 100 Most Creative people in Business.